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Abstract
Background: Ultrasound myocardial cavitation enabled treatment (MCET) is an image-guided method for tissue
reduction. In this study, a strategy of fractionated (multiple) treatments was tested for efficacy.
Methods: Dahl SS rats were anesthetized and prepared for treatment with a focused ultrasound transducer in a
warm water bath. Aiming at the anterior left ventricular wall was facilitated by imaging with a 10 MHz phased array
(10S, GE Vivid 7, GE Vingmed Ultrasound, Horten, Norway). MCET was accomplished at 1.5 MHz by pulse bursts of
4 MPa peak rarefactional pressure amplitude, which were intermittently triggered 1:8 from the ECG during infusion
of a microbubble suspension for cavitation nucleation. Test groups were sham, a 200 s treatment, three 200 s
treatments a week apart, and a 600 s treatment. Treatment outcome was observed by plasma troponin after
4 h, echocardiographic monitoring and histology at 6 wk.
Results: The impacts of the fractionated treatments summed to approximately the same as the long treatment; e. g.
the troponin result was 10.5 ± 3.2 for 200 s, 22.7 ± 5.4 (p < 0.001) for the summed fractionated treatments and 29.
9 ± 6.4 for 600 s (p = 0.06 relative to the summed fractionated). While wall thickness was not reduced for the
fractionated treatment, tissue strain was reduced by 35% in the target area relative sham (p < 0.001).
Conclusion: The ability to fractionate treatment may be advantageous for optimizing patient outcome relative to all-or
nothing therapy by surgical myectomy or alcohol ablation.
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Background
Hypertrophic cardiomyopathy (HCM) is a relatively
common genetic cardiovascular disease, occurring in
more than 1 in 500 people [1, 2]. HCM can occur in sev-
eral regions of the myocardium, and is particularly
troubling when restrictions occur in the left ventricular
outflow tract (LVOT). Patients may experience shortness
of breath, angina, palpitations, and even sudden death in
young athletes [3]. Hypertrophy leads to obstruction of
the LVOT in up to 75% of patients, either at rest or with
exercise. One-third of patients with obstruction remain
symptomatic after pharmacological therapy and are can-
didates for myocardial reduction [4]. Apical hypertrophy
is also troubling and currently has no available correct-
ive therapy [5].
Surgical septal myectomy is presently the primary
method for reduction of asymmetric septal hypertrophy
with perturbation of the mitral valve leaflets [6, 7]. This
invasive procedure simply deletes a volume of the myo-
cardium to relieve the obstruction. For HCM patients
with surgical myectomy, the interventricular wall thick-
ness was reduced by 18% from 19.4 to 15.9 mm [8].
Transcatheter septal ablation with alcohol has been
developed as an alternative to surgery [7], and has
achieved some success in terms of safety and efficacy
[9]. The immediate therapeutic benefit appears to
depend on akinesis of the effected region, rather than an
immediate reduction in size. However, septal thinning
develops gradually after alcohol treatment and reduc-
tions from 23.7 to 18.0 mm (24%) have been reported
after 6 months [10]. The alcohol procedure results in a
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volume of complete necrosis, which progresses to
myocardial fibrosis and scar [11]. This procedure has
a high incidence of heart block (about 20%) requiring
permanent pacemaker [4], and healing of the alcohol
infarction to massive scar carries a risk of serious
arrhythmia [12]. These procedures are comparable
with low rates in overall mortality and sudden cardiac
death after treatment [9].
An alternative to myectomy or alcohol ablation would
be a useful additional option for some patients if it were
less invasive or more precise in creation of myocardial
reduction or akinesis, and could be utilized for apical or
other presentations of hypertrophy not suitable for the
established treatments. We have developed a novel ultra-
sonic method of myocardial treatment, which employs
intermittent pulsed ultrasound exposure of the myocar-
dium during infusion of a microbubble contrast agent.
Infused microbubbles are destroyed by relatively high
pressure amplitude pulses, and the intermittent delay
allows capillaries to refill with blood containing fresh
microbubbles. The microbubble destruction nucleates
ultrasonic cavitation within the focal zone, leading to
randomly scattered microlesions each with capillary
injury and one or a few lethally injured cardiomyocytes.
This nonthermal myocardial cavitation-enabled treat-
ment (MCET) method was based on the diagnostic myo-
cardial contrast echocardiography technique using
contrast destructive pulses with observation of contrast
refill for perfusion assessment. Scattered cardiomyocyte
injury was detected for myocardial contrast echocardiog-
raphy [13], but MCET employs higher than diagnostic
pressure amplitudes for therapeutic myocardial reduc-
tion [14]. This treatment produces microlesions which
accumulate with each intermittent pulse allowing adjust-
ment of microlesion density from modest fractions of
tissue volume to more dense distributions within a
targeted focal zone [15]. The effected region can be
accurately created by the image-guided placement of the
ultrasonic focus. Echocardiography is the gold standard
method for HCM diagnosis and treatment follow up.
The combination of MCET with diagnostic imaging
presents a compelling new concept of non-invasive and
highly controlled HCM therapy.
In studies with rats, MCET has utilized a small
1.5 MHz focused transducer aimed with guidance from
a 10 MHz cardiac probe on a GE Vivid 7 Dimension
ultrasound machine [14]. Highly effective treatment
involves 10 cycle pulses of 4 MPa peak rarefactional pres-
sure amplitude delivered intermittently each 8 heartbeats
during continuous IV infusion of microbubble contrast
agent suspension for 10 min of lesion accumulation. Most
pulse-triggers produced premature complexes (PCs) in
the ECG, when triggered at the end of systole, which are
indicative of treatment progress [16]. If pulse triggers
produce few PCs, then the resulting treatment effect will
be inadequate. Troponin I measurements in blood sam-
ples provide an overall measure of treatment impact. Wall
thickness and wall strain and displacement are measured
by echocardiography, and fibrosis is assessed in histology.
Longer-term maturation of the myocardial volumes
with MCET microlesions was studied to assess the
potential therapeutic effect in normal Dahl-SS rats [17],
and in the SS-16BN rat model of HCM [18]. The conso-
mic Dahl SS rat with chromosome 16 from brown
Norway rats develops progressive left ventricular (LV)
hypertrophy without hypertension [19]. For normal rats,
significant inflammatory response to the injury increased
the heart wall thickness the day after treatment, as
measured by echocardiography [17]. After 4 weeks, no
significant tissue reduction was noted in the treated
region with scattered areas of tissue fibrosis. For the
HCM model rats, the inflammatory response was greatly
reduced by adjuvant steroid given at treatment and adju-
vant treatment with an angiotensin II receptor blocker
was used to minimize scarring [18]. MCET rapidly pro-
duced a significant reduction in myocardial strain rate
and endocardial displacement. At 28 d post therapy, the
targeted wall thickness was significantly reduced by
16.2% (p < 0.01) relative to shams, and strain rate and
displacement were, reduced by 34% and 29%, respect-
ively, which are sufficient for therapeutic treatment.
An important advantage of MCET, for example, rela-
tive to alcohol ablation, is the ability to monitor
outcome by echocardiography, and re-treat desired seg-
ments of the myocardium by image guided placement of
the focal zone. This is limited by the depth of the focal
zone, so that in rats, the 1.5 MHz focal zone passes
through the heart giving lesions on the anterior, poster-
ior and septal regions. A system designed for MCET in
humans would have the ability to target desired regions
more specifically, and to rapidly treat by intermittent
scans. Another advantageous feature is the ability to
gradually accumulate microlesions to form a desired
“macrolesion” treatment impact. A conservative treat-
ment could be augmented at a later date and adjusted in
shape and size as desired. This present study was
designed to test the idea of multiple treatment accumu-
lation using the normal rat model. Three treatments of
200 s, spaced a week apart, were compared to 3 sham
200 s treatments, one 200 s treatment and one 600 s
treatment (i. e., the 10 min highly efficacious protocol).
Methods
Animal preparation
All in vivo animal procedures were conducted with the
approval and guidance of the University Committee on
Use and Care of Animals of the University of Michigan.
Normal Dahl SS rats (Charles River, Wilmington, MA,
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USA) were used for this study for comparison to earlier
work [14, 17]. For ultrasound treatment, the rats were
anesthetized by intraperitoneal injection of ketamine
(90 mg kg−1) and xylazine (9 ml kg−1) and the left thorax
was shaved and depilated for ultrasound transmission to
the heart. A 24 gauge cannula (BD Angiocath, Becton
Dickinson Infusion Therapy Systems, Sandy, UT, USA)
was inserted into the tail vein for intravenous injections
of contrast agent. The rats were mounted on a posi-
tioning board and needle electrodes were placed in
the forelegs and left hind leg for detection of the
electrocardiogram (ECG). The board was then placed
in a 38 °C water bath filled with degassed water
which maintained the rat body temperature and pro-
vided coupling for ultrasound scanning and treatment.
All rats were allowed to waken and had follow-up
monitoring for 6 weeks. For follow-up echocardiog-
raphy or other exams, the rats were anesthetized with
1–4% isoflurane in oxygen (Isotec 4, Surgivet Inc.
Waukesha, WI USA), and scanned in the right lateral
recumbent position on a warming pad.
Ultrasound
Ultrasound exposure for treatment was provided by a la-
boratory system with guidance by diagnostic ultrasound
imaging, as described previously [14]. Briefly, the treat-
ment system consisted of a function generator for gener-
ating a train of 10 cycle pulses at 4 kHz PRF (model
3314A function generator, Hewlett Packard Co., Palo
Alto CA, USA). An arbitrary waveform generator was
used for amplitude modulation of the pulse train to give 8
pulse bursts (model 33220A, Agilent Technologies,
Loveland CO, USA). A power amplifier (A-500, Electronic
Navigation Industries, Rochester NY, USA) elevated the
signal for driving the transducer. The rat ECG signal was
amplified (Model ECGA amplifier, Hugo Sachs
Elektronik, Harvard Apparatus, March, Germany) and
displayed on an oscilloscope (Model TDS 520 B,
Tektronix Inc., Beaverton, OR, USA), which was used
to trigger the pulse bursts at end of systole. A
1.5 MHz single element transducer (Panametrics
A3464, Olympus, Waltham, MA, USA) with 1.9 cm
diameter and 3.8 cm focal length was used for the
treatment. The pulse exposure parameters were mea-
sured with a calibrated hydrophone (model HMA0200
membrane hydrophone, Onda Corp. Sunnyvale CA
USA), and used to adjust the function generator volt-
age to generate a 4 MPa peak rarefactional pressure
amplitude (PRPA). The chest wall attenuation at
1.5 MHz is about 1.1 dB/cm/MHz [20], which
reduces the PRPA at the heart to about 3.6 MPa after
passing through the 5 mm thick chest wall. The
equivalent in situ MI (the derated PRPA divided by
the square-root of frequency) was therefore about 2.9;
for reference, the regulatory upper limit on the MI
for diagnostic ultrasound is 1.9. The −6 dB beam diameter
was measured at the focus to be 3.5 mm. The focus was
targeted to the anterior surface of the heart with the aid of
10 MHz diagnostic ultrasound imaging (GE Vivid 7 with
10S probe, General Electric Corp., Cincinnati OH, USA),
as previously described [14]. Treatments were either 200 s
or 600 s in duration.
Ultrasound contrast agent
A continuous infusion of a microbubble suspension
was given during treatment. The suspension was
prepared to closely duplicate the ultrasound contrast
agent Definity® (Lantheus Medical Imaging, Inc., N.
Billerica, MA), as described previously [17, 21]. This
suspension served as the source of in vivo cavitation
nuclei for MCET, and contained 3.7 ± 0.3 (109)
microbubbles per mL of 1.8 ± 0.11 μm diameter. This
was diluted in sterile saline in a 5 ml syringe, and
infused via tail vein with a syringe pump at a rate
providing 5 μl/kg/min of agent.
Table 1 Parameters for the rats at initial anesthesia
(average ± standard deviation)
Weight HR SpO2
Group Treatment n gm BPM %
A 3× sham 5 372 ± 18 265 ± 23 82 ± 2
B 3 × 200 s 6 391 ± 12 261 ± 11 90 ± 4
C 200 s 6 405 ± 20 246 ± 14 85 ± 5
D 600 s 6 395 ± 29 253 ± 18 86 ± 4
The groups of rats were very similar, with some variation in weight due to the
experimental plan having a staggered start (rats differing in age by up
to 3 weeks)
Fig. 1 Trends in the mean body weight for each of the groups.
The steroid treatment induced a brief period of weight loss for
each treatment session so that the fractionated treatment groups,
both sham and exposed, had three brief periods of weight loss
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Adjuvant treatment
Adjuvant treatment with methylprednisolone (methyl-
prednisolone acetate injectable suspension, Depo-
Medrol, Pfizer Inc. New York, NY USA) and losartan
(Losartan Potassium, TEVA Pharmaceuticals USA, INC.
North Wales, PA) was given to the rats to improve the
treatment outcome. Roberts et al. showed that initial in-
flammation and subsequent scarring from myocardial
infarction in rats was reduced by high dose methylpred-
nisolone treatment [22]. For MCET, methylprednisolone
reduced the inflammatory response to microlesion injury
and the swelling of the treated area [18]. Doses of 1 mg/
kg were given at treatment and at 4 and 24 h post treat-
ment. The steroid treatment had a negative effect on the
weight of the rats, and weights were measured at treat-
ment and each day of follow-up. de Carvalho Frimm et
al. reported that losartan, an angiotensin II receptor an-
tagonist used for blood pressure control, reduced infarct
size and collagen volume fraction (indicative of scarring)
at 4 weeks post infarct [23]. For this study, losartan was
given daily by gavage at 10 mg/kg in water, starting 1
day after ultrasound treatment and continuing for until
the conclusion of the study.
Measured endpoints
Plasma troponin was measured in samples obtained 4 h
after treatment, which provided a general measure of
overall heart injury. Plasma troponin I (CTNI-2-HSP,
Rat Cardiac Troponin-1 ELISA kit, Life Diagnostics Inc.
West Chester, PA USA) is a sensitive measure of cardiac
injury in rodents with essentially zero background in
controls [24]. In previous work, the plasma troponin
correlated with wall thinning observed in HCM model
rats at 4 w post treatment [18]. The cumulative release
of troponin is a useful measure of total injury [25].
Left ventricular wall thickness and ejection fraction
was measured by echocardiography at treatment (D0),
the next day (D1) to assess the inflammatory increase in
wall thickness, after 1 week (D7), and at euthanasia. In
addition, the local reduction in kinetic motions of heart
wall was measured by echocardiography using image
analysis software (EchoInsight, Epsilon Imaging, Ann
Arbor MI USA) as described previously [18]. The
circumferential strain fraction (elasticity) and the
displacement of the endocardium from diastole to systole
were evaluated. For repeated measurements, the treated
region could be identified accurately by the acoustic
window and by hyperechogenicity in the ultrasound image
(caused by the inflammatory response or fibrosis for later
exams). These were compared to matched regions in
sham treated hearts.
The healing and scar formation was also evaluated
histologically, as described previously [18]. The hearts
were fixed in an end-diastolic configuration [26], giving
with dimensions approximating the dimensions observed
by echocardiography. Histological slides were processed
at the Histology Core of the University of Michigan
Dental School with Masson’s trichrome staining to show
fibrosis. The wall thickness change was estimated
relative to shams. In addition, the approximate percentage
Table 2 Results for the percentage of pulse triggers resulting in premature complexes (PCs) in the ECG, and for the plasma troponin
at 4 h (average ± standard deviation)
Premature Complexes (%) Plasma Troponin (ng/ml)
Group Exp 1 Exp 2 Exp 3 Mean Exp 1 Exp 2 Exp 3 Total
A 0.2 ± 0.5 0 ± 0 0.4 ± 0.9 0.2 ± 0.5 0.3 ± 0.02 0.3 ± 0.02 0.48 ± 0.03 1.1 ± 0.04
B 99 ± 2 97 ± 2 97 ± 5 97 ± 2 11.1 ± 3.3 5.6 ± 2.0c 6.0 ± 1.4c 22.7 ± 5.4
C 96 ± 6 96 ± 6 10.5 ± 3.2 10.5 ± 3.2
D 94 ± 5 82 ± 7a 76 ± 10† 85 ± 10b 29.9 ± 6.4 29.9 ± 6.4
PC results for the 600 s treatment were assessed for each 200 s period, for comparison to the fractionated treatments. Results for the multiple treatments were
summed to give the total effect. PCs were significantly less than in the 1st period for the successive periods of the 600 s treatment (a), and the mean was
significantly less than the mean for the fractionated treatments (b). Troponin release was significantly reduced for the 2nd and 3rd of the fractionated
treatments (c)
Fig. 2 Results for the percentage of pulse triggers resulting in premature
complexes in the ECG (average ± standard deviation) for 200 s (yellow),
600 s (red) and fractionated treatment (blue). PCs were significantly less
than in the 1st period for the successive periods of the 600 s
treatment (†), and the total was significantly less than the total
for the fractionated treatments (*)
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of the treated areas with fibrosis was assessed by image
analysis of blue Masson’s staining.
Experimental plan
Twenty-four Dahl SS rats, 20–22 weeks of age, were
used for this study in 4 groups, listed in Table 1. The
groups were: A. sham multiple treatment (5 rats), B.
three 200 s treatments (6 rats), C. single 200 s treatment
(6 rats) and D. single 600 s treatment (6 rats). One rat
died in animal housing before use, which was subtracted
from the sham group. One rat from the multi-treatment
group died 35 d after beginning treatment, with that
final datum lost from the data set. Rats were randomly
chosen for each group. Four rats were used each of 12
treatment days, which were selected from the groups in
a defined pattern to balance the order of handling in
each group. This was complicated by the multiple
treatments. Each treatment day, 3 rats received one
of their multiple treatments (alternating 1A and 2B
with 1B and 2A), and one rat received its single treat-
ment (alternating group C or D).
Results are reported as the means plus or minus one
standard deviation, or plotted with standard error bars.
Statistical analysis was performed (SigmaPlot for
Windows V. 11.0, Systat Software Inc., San Jose CA,
USA). Student’s t-tests were used to compare means of
the measured parameters, with statistical significance
assumed at p < 0.05.
Results
The physiological parameters for the groups are listed in
Table 1. All had approximately the same weight, heart
rate under anesthesia and SpO2 under anesthesia. The
rats all received the steroid treatment at each exposure
session. Therefore the fractionated exposure with three
200 s exposures had 3 dose regimens of the steroid. The
steroid treatment produced a brief period of weight
reduction in the Dahl SS rats, considered to be an
adverse reaction. The weight trends for each group are
plotted in Fig. 1. The fractionated treatment groups
(sham and exposed) had quite similar trends of repeated
brief weight loss, which indicates the weight changes
were due to the steroid, and not the MCET treatment.
The results for PCs and troponin release at each treat-
ment are listed in Table 2. The PCs for the 600 s group
are broken down into 200 s segments for comparison to
the fractionated treatment group, as shown in Fig. 2. For
the fractionated treatment groups, the results for the
three treatments are also totaled for comparison to the
600 s group. There was a significant trend for the PCs to
decline during the 600 s exposures such that the 2nd
and 3rd 200 s periods had significantly fewer PCs than
the first period, and the total was significantly less than
for the fractionated treatment. Interestingly, although
PCs remained the same (≥97%), troponin release for
the 2nd and 3rd fractions of the fractionated treat-
ment, which were about the same, were significantly
less than the first fraction (p < 0.01). The troponin
total for the fractionated treatment was somewhat less
than for the single 600 s treatment, but the difference
was not significant (p = 0.06).
The results of the follow-up monitoring are listed in
Table 3 for the baseline and end (i. e. the final exam
Table 3 Results for treatment impact given as the baseline compared to end results for the final exam before sacrifice
(mean ± standard deviation)
Echo wall (mm) Ejection Fraction Echo Strain (%) Displace. (mm) Histo wall Fibrosis
Group Baseline End Baseline End Baseline End Baseline End mm Area %
A 1.7 ± 0.1 1.7 ± 0.1 80 ± 3 77 ± 1 51 ± 7 46 ± 4 0.88 ± 0.13 0.76 ± 0.08 2.3 ± 0.4 0
B 1.7 ± 0.1 2.0 ± 0.1** 79 ± 1 75 ± 2** 45 ± 8 30 ± 5** 0.92 ± 0.06 0.76 ± 0.08* 2.4 ± 0.2 40 ± 10a
C 1.8 ± 0.1 1.9 ± 0.2* 80 ± 4 77 ± 5 46 ± 5 36 ± 8* 0.87 ± 0.08 0.84 ± 0.11 2.4 ± 0.4 29 ± 16a
D 1.9 ± 0.2 1.5 ± 0.2** 79 ± 3 65 ± 6** 45 ± 7 25 ± 7** 0.88 ± 0.08 0.54 ± 0.11** 1.8 ± 0.3a 49 ± 8a
Significant differences versus baseline denoted by * for p < 0.05 or ** for p < 0.01. Significant difference versus sham (A) denoted by a. In addition, the fibrosis
was higher in D than in C (p < 0.05), but there was no significant differences for the other comparisons (B versus C, and B versus D)
Fig. 3 The trends in echocardiographic wall thickness for the groups.
Treatment induced immediate swelling which was notable the next
day, then receded after 1 week and at the end of monitoring. Only the
600 s treatment gave a significant reduction in wall thickness (p < 0.01)
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before sacrifice) echocardiographic wall thickness, ejec-
tion fraction, wall strain and endocardial displacement
determined from the echocardiographic images, the wall
thickness measured in histological samples, and the
percentage of fibrotic area seen in Masson’s trichrome
slides within the target region. The results were signifi-
cantly different from baseline for all treated groups. The
treatment caused wall swelling after 1 day, which
decreased for subsequent measurements at 1 week and
at the end of the monitoring. These trends are shown in
Fig. 3. For the fractionated treatments, the 3 episodes of
swelling and recovery are clearly apparent. Of note, the
600 s treatment group had the wall thickness recede to
pre-treatment dimensions, equal to the sham values,
after 1 week. The final wall thickness was significantly
increased for the 200 s and fractionated treatment, but
significantly reduced for the 600 s treatment.
The heart samples showed visual evidence of fibrosis,
as shown in Fig. 4. The fibrosis had a characteristic
white circular appearance which corresponded to the
beam target area. In addition, for the 600 s groups, an
extra region of fibrosis was sometimes clearly evident
toward the upper right of the target area; the clearest
example is shown in the figure. In histology, the fibrosis,
stained blue in Masson’s trichrome histology (Fig. 4),
was evident as scattered microlesion regions in the 200 s
and fractionated exposures. In the 600 s treatment
shown, the section reveals a thin region of tissue erosion
on the anterior surface (possibly, giving the very bright
white appearance on the heart surface).
Discussion
MCET produces scattered microlesions encompassing a
few lethally injured cardiomyocytes, which accumulate
with each triggered pulse burst. The total “macrolesion”
can be sufficient for therapy of hypertrophic cardiomy-
opathy both in terms of heart tissue volume reduction
and in akinesis of wall motion and strain. Previous work
with Dahl SS rats had demonstrated substantial tissue
impact, with minimal impact on heart function after
healing for single long (600 s) treatments [17, 18]. Adju-
vant treatment with methylprednisolone and losartan
reduce the initial swelling and aid in reduction of fibrosis.
In this study, the strategy of fractionated treatment which
could allow graded treatment and retreatment adjust-
ments was assessed in normal Dahl SS rats. This strategy
is an important distinction from surgical myectomy and
alcohol trans-catheter ablation, the currently accepted
treatments, because those methods are essentially single
conclusive treatments.
This study demonstrated that repeated treatments
were well tolerated and produced incremental increases
in effect as measured by troponin release. However, the
2nd and 3rd treatments a week apart were less effective
than the first. The treatment did not produce a reduc-
tion in wall thickness, which remained greater than the
baseline (Fig. 3). However, the akinesis produced by the
fractionated treatment was significant. Akinesis induced
by alcohol ablation appears to be responsible for the
immediate relief of symptoms [10], and should be thera-
peutic also for the MCET method.
Fig. 4 Selected examples of the hearts for each group. Photographs are shown of hearts for groups A-D (scale bar 5 mm), and corresponding
histological sections (scale bar 2 mm) stained with Masson’s trichrome to reveal fibrosis (blue). For the 600 s treatment (D), the wall is noticeably
thinned in the target area, including some erosion of the heart surface
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The single 600 s treatment, used for previous chronic
studies [17, 18], was remarkably effective in this study
with a 21% reduction in wall thickness (Table 3). This
effectiveness may have included a secondary mechanism
of injury. The heart shown in Fig. 4 from group D has
an exaggerated fibrotic region which appears to be
outside the targeted region. For the fractionated treat-
ment, the real time indicator of PCs was the same for
the 3 fractions, but declined for each 200 s segment of
the 600 s treatment, while apparently yielding greater
impact. One possible explanation for the extra fibrosis
region is heart motion due to breathing, which periodic-
ally could shift the target point of the ultrasound beam.
However, the histologically observed result (Fig. 4)
seemed to be greater than within the target region, and
included a surface layer of myocardial ablation not
unlike that seem in ischemia induced infarcts. Thus,
another explanation for the high efficacy of the 600 s
treatment may be local ischemia resulting from the
tissue swelling or microvascular occlusion. This possibility
should be investigated and minimized to allow better
treatment control for the desired outcome of scattered
microlesions within a functional treated volume.
Conclusions
In conclusion, the strategy of MCET treatment fraction-
ation was shown to be feasible, and represents a poten-
tial advantage relative to currently accepted therapy. A
possible adverse effect of partial ablation was seen for a
600 s treatment, not previously noted for MCET. How-
ever, this was not noted for the fractionated treatment.
An unexpected contrast was found for the resulting left
ventricular wall thickness, which was increased for
fractionated and decreased for continuous treatment.
Previously, wall thickness reduction was not seen for
normal Dahl SS rats [17] without adjuvant treatment but
was seen for the SS-16BN rat model of HCM with the
adjuvant treatments [18]. Further study of the safety and
efficacy of MCET is needed, especially for larger animal
models such as cats [27], which have a more clinically
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